seminal vesicles is only 4-5-fold higher. This difference in relative potency is due to the fact that MENT does not 1 Steroid Research Laboratory, Institute of Biomedicine, undergo 5α-reduction (Agarwal and Monder, 1988) to be used as the androgenic component of a hormonal 7α-Methyl-19-nortestosterone (MENT) is a potent synmale contraceptive and in long-term androgen replacement thetic androgen that is resistant to 5α-reductases and therapy of hypogonadal men (Sundaram et al., 1993) . therefore less prone to over-stimulate the prostate.
to be used as the androgenic component of a hormonal 7α-Methyl-19-nortestosterone (MENT) is a potent synmale contraceptive and in long-term androgen replacement thetic androgen that is resistant to 5α-reductases and therapy of hypogonadal men (Sundaram et al., 1993) . therefore less prone to over-stimulate the prostate.
It is
The pharmacokinetics and acute pharmacodynamic changes a good candidate for implant administration in long-term after i.m. administration of MENT have not been studied androgen replacement therapy for hypogonadal men or as previously in men. Although the administration of MENT part of a male contraceptive system. To investigate the in the future will not be i.m. (Sundaram et al., 1993) , pharmacokinetics of MENT after i.m. administration, information on the basic pharmacokinetic and pharmacosingle i.m. injections of 2, 4 or 8 mg of micronized MENT dynamic properties of MENT is necessary for the developwere given in aqueous suspension to 18 healthy men in two ment of MENT dosage forms suitable for long-term androgen clinics. Blood was sampled frequently for 8 h and 1, 2, 3, replacement. We therefore measured the concentrations of 4 and 9 days after the injections. Serum MENT concentra-MENT, testosterone, luteinizing hormone (LH), follicle tions were determined by radioimmunoassay. Peak MENT stimulating hormone (FSH) and sex hormone-binding globulin concentrations were dose-dependent and were reached (SHBG) before and after single i.m. MENT injections, as about 1-2 h after the injections. Doubling the dose of well as during and after a series of six i.m. MENT injections MENT resulted in an increase of 60% in peak serum given at 24 h intervals. gen whose biological potency in animals is several-fold (range 19.2-24.5 ). The 12 Chilean subjects were aged 20-29 years specific antigen were obtained pre-admission, and 2 and 24 days after the last injection. (24 Ϯ 0.9). Their mean body weight was 71 Ϯ 3.1 kg (range 57-96 kg), and body mass index 24.0 Ϯ 1.0 (range 19.9-31.3). Assays None of the Finnish subjects was overweight. Three Chilean Concentrations of MENT were measured at The Population Council subjects were slightly overweight (body mass index 25-30), and by radioimmunoassay as described previously (Kumar et al., 1990) . one was obese (body mass index 31.3, height 175 cm, weight 96 kg).
The detection limit of the assay was 28 pg/ml, its intra-assay All subjects were judged to be normal as assessed through coefficient of variation (CV) 7.0% and its interassay CV 13.8%. medical history, general physical examination and clinical chemistry
The cross-reactivity of testosterone in the MENT radioimmunoassay measures including blood count, liver and kidney function tests, was 1.1%. The concentrations of testosterone, FSH, LH and SHBG lipid profile and assay of circulating concentrations of prostatewere measured in the Steroid Research Laboratory, Institute of specific antigen. None of the subjects studied had any personal or Biomedicine, University of Helsinki, Finland. Serum testosterone family history of prostate cancer nor any other contraindications concentrations were determined by conventional RIA according to for androgen administration. None had been using any regular a standard operating procedure from the World Health Organization medication and none obtained any medication during the study.
(WHO; Sufi et al., 1990) . The limit of detection was 0.5 nmol/l, The pre-admission serum testosterone, LH and FSH concentrations the intra-assay CV 6.8% and the interassay CV 13.3%. The crossof all subjects were within normal limits except for two subjects reactivity of MENT in the testosterone radioimmunoassay was in study 2 who had pre-admission FSH concentrations slightly 1.2%. The concentrations of FSH, LH and SHBG were measured under the normal limit of 1.0 U/l (a Finnish subject in the 4 mg by time-resolved fluoroimmunoassays using commercially available group had a baseline FSH concentration of 0.8 U/l, and a Chilean kits (DELFIA ® , Wallac OY, Turku, Finland). The limit of subject in the 2 mg group had a baseline FSH concentration of detection for LH was 0.05 IU/l, the intra-assay CV 5.0% and 0.6 U/l).
the interassay CV 11.7%. The limit of detection for FSH was The studies were conducted in accordance with good clinical 0.05 IU/l, the intra-assay CV 3.4% and the interassay CV 4.9%. practice guidelines and the Declaration of Helsinki. The ethics For SHBG, the limit of detection was 0.8 nmol/l, the intra-assay committees of both clinics and the institutional review board of CV 8.9% and the interassay CV 7.0%. All hormone and SHBG the Population Council approved the studies. All subjects gave measurements were made in duplicate, and duplicates with a CV written informed consent before enrolment. All subjects completed Ͼ15% were re-assayed. The other clinical chemistry assays were the trials.
carried out in local laboratories.
Design of the study Pharmacokinetic calculations and statistical analysis MENT acetate was supplied by SRI International, Menlo Park,
We used the pharmacokinetic calculation methods described by CA, USA, and hydrolysed to MENT at the Population Council's Rowland and Tozer (1989) , and Greenblatt and Koch-Weser (1975) . Laboratory in New York, USA. An aqueous suspension of To estimate the half-life of MENT after i.m. administration an micronized MENT was used for the i.m. injections. All doses exponential equation in the form c ϭ c 0 ϫ e -kt was fitted to the were given in an injection volume of 0.5 ml. In Finland the combined concentration data from all subjects using a least squares injections were given deep in the deltoid muscle and in Chile in fit (c is the concentration at time t, c 0 is the concentration the gluteus muscle. Blood samples were collected from an i.v. extrapolated to zero time, e is the base of natural logarithms, k is the elimination rate constant, and t is time.) The elimination catheter fitted into a superficial vein on the back of the hand. The half-life was calculated by dividing the natural logarithm of 2 by blood samples were allowed to clot and the sera were separated the elimination rate constant. The areas under the concentrationby centrifugation and stored at -20°C in plastic test tubes time curves (AUC) were computed by the linear trapezoidal rule until assayed. from 0 to 24 h. The plasma clearance values were calculated by For study 1, the subjects in each clinic were divided into three dividing the doses by the AUC values. groups of three. Each subject in the first group was given 2 mg Analysis of variance was used to test whether there were of MENT. Subjects in the second and third groups received 4 and significant differences between clinics and between dose groups in 8 mg of MENT respectively. The first blood sample was collected pharmacokinetic parameters and basal hormone concentrations. just before injection, the following 10 samples exactly 15, 30, 60, Significant variations over time in hormone concentrations were 90, 120, 180, 240, 300, 360 and 480 min after injection and the evaluated by analysis of variance for repeated measures. For the next samples 1, 2, 3, 4 and 9 days after injection. Blood samples comparison of the maximal effect of MENT on each hormone, for clinical chemistry measures including blood count, liver and the relative change was calculated by subtracting from each kidney function tests, lipid profile [total cholesterol, high density hormone concentration the baseline value of the same subject and lipoprotein (HDL)-cholesterol, low density (LDL)-cholesterol and dividing the difference by the baseline value. For each subject, triglycerides], and assay of prostate-specific antigen were obtained the greatest relative change was identified for each hormone. The before treatment and 4 and 9 days after injection.
purpose of this transformation was to remove the effect of betweenFor study 2, the subjects in each clinic were divided into three subject variations in baseline hormone concentrations. The maximal groups of four. Each subject in group 1 was given 1 mg of relative changes were compared using analysis of variance. In all MENT each morning for 6 consecutive days. Subjects in groups statistical tests, P Ͻ 0.05 was considered statistically significant. 2 and 3 received injections of 2 mg and 4 mg according to the All results are given as the mean Ϯ SE. same schedule. Blood samples were drawn before treatment and each day just before the MENT injection and thereafter at the same time in the morning 2, 3, 5, 9, 13 and 24 days after the Table I . MENT concentrations in Values are mean Ϯ SE. c max ϭ peak serum concentration, t max ϭ time to peak serum concentration, AUC ϭ area under the concentration-time curve. The mean clearance for all 18 subjects was 1790 Ϯ 140 l/day. all samples taken after the 24 h samples were below the injection of single doses of MENT followed the circadian patterns of these hormones (data not shown). detection limit of the assay. The pharmacokinetic parameters are shown in Table II . There were no statistically significant Study 2: six daily intramuscular injections of MENT differences in the pharmacokinetic parameters between the two clinics, and hence we combined the data of each dose
The concentrations of MENT in the serum samples taken during this part of the study were all below the detection group from both clinics. The peak MENT concentrations (c max ) were dose-dependent and the differences between the limit of the assay. This is consistent with the observation in study 1 that serum concentrations of MENT were three dose groups were significant (P ϭ 0.028). Over the 4-fold dose range tested, each doubling of the dose of undetectable or almost undetectable 24 h after injection. Serum testosterone concentrations in each dose group from MENT resulted in an increase of~60% in c max . The time to reach peak values (t max ) appeared to be longer at the each clinic are shown in Figure 1 . The baseline testosterone concentrations in the Finnish subjects were significantly higher doses, but the differences between dose groups were not significant. The values for AUC were dose-dependent, lower than those in the Chilean subjects (15.5 Ϯ 1.2 versus 20.6 Ϯ 1.7 nmol/l, P ϭ 0.029). The decrease in testosterone and the differences between dose groups were significant (P ϭ 0.002). The differences in clearance rates between concentrations after the i.m. injections was significant (P Ͻ 0.001). The mean of the maximal relative decrease in testosdose groups were small and not significant, and therefore a mean clearance rate was calculated for all subjects. The terone concentrations was dose-dependent: 41 Ϯ 4, 59 Ϯ 3 and 74 Ϯ 5% in the groups who received the 1, 2 or 4 mg doses, mean clearance rate was 1790 Ϯ 140 l/day. To estimate the elimination half-life of MENT after a single i.m. injection, respectively. The differences between dose groups were statistically significant (P Ͻ 0.001). we combined the concentration versus time data of all subjects. The data fitted well with the exponential equation Serum LH concentrations by dose group and clinic are presented in Figure 2 . There were no significant differences c ϭ c 0 ϫ e -kt , and the estimated elimination half-life was 224 min.
in baseline LH concentrations between clinics. The decrease in LH concentrations after the i.m. injections was significant The concentrations of testosterone, LH and FSH after the Figure 1 . Mean (Ϯ SE) serum testosterone concentrations in the subjects of study 2 before, during, and after the series of six consecutive daily i.m. 7α-methyl-19-nortestosterone (MENT) injections by dose group and by clinic (n ϭ 4 per group). The black triangles indicate the six injection days (days 1-6). Day 0 samples were taken before enrolment, and day 1 samples were taken just before the first injection.
(P Ͻ 0.001). The mean of the maximal relative decrease in from 31 Ϯ 2.2 (baseline) to 26 Ϯ 2.1 nmol/l (two days after the last injection). This decrease in SHBG concentrations after LH concentrations was dose-dependent: 52 Ϯ 3, 62 Ϯ 6 and 70 Ϯ 5% in the groups who received 1, 2 or 4 mg doses, the i.m. injections was significant (P Ͻ 0.001). There were no significant differences either in baseline concentrations or in respectively. The differences between dose groups were statistically significant (P ϭ 0.048).
the mean decreases between clinics or between dose groups. Serum FSH concentrations in each dose group of each Clinical chemistry and safety clinic are shown in Figure 3 . The baseline FSH concentrations in the Finnish subjects were significantly higher than those of
The subjects did not report any adverse effects. The total neutrophil count decreased to 1.7ϫ10 9 /l in two Finnish subjects the Chilean subjects (3.9 Ϯ 0.4 versus 2.4 Ϯ 0.2 U/l, P ϭ 0.009). The decrease in FSH concentrations after the i.m. in study 2. Total serum cholesterol in one Finnish subject in study 1 increased from 4.7 to 6.3 mmol/l, and his LDLinjections was significant (P Ͻ 0.001). The mean of the maximal relative decrease in FSH concentrations was dosecholesterol concentration increased from 2.6 to 4.5 mmol/l. In addition, three other Finnish subjects in study 1 and three dependent: 25 Ϯ 5, 41 Ϯ 5 and 57 Ϯ 4% in the groups who received 1, 2 or 4 mg doses, respectively. The differences Finnish subjects in study 2 had increases in total serum cholesterol from desirable values to borderline high values. In between dose groups were statistically significant (P ϭ 0.001).
By day 15, nine days after the last injections, all hormone study 1, two Finnish subjects and one Chilean had clear increases in their triglyceride concentrations. The greatest concentrations had returned to near their baseline values and the concentrations in the last two samples were similar; hence increase was from 0.9 to 3.3 mmol/l. In study 1, one Finnish subject had a small increase in aspartate aminotransferase the last two samples are not shown in the Figures.
In addition to the decreases in hormone concentrations, clear (AST) concentrations, while another had a small increase in alanine aminotransferase (ALT) concentrations. Lactate decreases in SHBG concentrations were also observed. The mean serum SHBG concentration of all 24 volunteers decreased dehydrogenase (LD) increased slightly in three Chilean subjects. In study 2, one Finnish subject had an increase in than the 40 min elimination half-life determined using a single i.v. dose of 0.5 mg MENT. This difference is almost certainly AST from 27 to 72 U/l and an increase in LD from 351 to explained by the slow absorption of MENT from the i.m. 530 U/L (upper limit, 450 U/l). In addition, another Finnish injection site (Rowland and Tozer, 1989) . If absorption is slow subject and three Chilean subjects also had increases in LD.
enough, it is rate-limiting in the decay phase of MENT The highest increase in LD among the Chileans was from 175 concentrations, and the estimated half-life corresponds to the to 383 U/l, (upper limit, 225 U/l). The same subject also had absorption half-life. Since MENT is poorly soluble in water, an increase in AST from 28 to 123 U/l (upper limit, 37 U/l) its absorption from muscle could be relatively slow (Greenblatt (note the different upper limits of several liver function test and Koch-Weser, 1975 ). The striking difference in the t max results in Finland and Chile. This is due to differences in values between the 8 mg groups in Finland and in Chile is laboratory methods). In both clinics and both studies, the explained by the fact that one subject in Finland had the peak serum concentrations of prostate-specific antigen remained concentration of MENT in the first sample collected (15 min well below the upper limit of the reference range (4 µg/l).
after the injection). The cause is unclear, but the drug may have been injected in the vicinity of a vessel, leading to rapid Discussion absorption. We here report the first study on the pharmacokinetics of The changes in the serum concentrations of testosterone, MENT given i.m. to healthy men. The pharmacokinetics of LH and FSH after the single i.m. MENT injections were MENT given i.v. have been studied previously (unpublished not reported, since in the absence of a placebo group, the results). The mean clearance rate after i.m. administration possible effect of MENT on these concentrations cannot be (1790 Ϯ 140 l/day) was not very different from the cleardistinguished from natural circadian variation (Wisser and ance rate determined following i.v. administration, 2100 Ϯ Breuer, 1981; Bridges et al., 1993) . On the other hand, it is 160 l/day. In contrast, the half-life estimated from the data of important to note that circadian variation could not influence the results of the study of six daily MENT injections, since in the present study (224 min) was more than five times longer this study, all blood samples for hormone assays were taken A significant decline with age in circulating testosterone concentrations has been described (Dabbs, 1990) . There may at the same time in the morning.
The deviations from reference ranges observed in some also be true differences between these two ethnic groups in hormone concentrations. Still another possible explanation is clinical chemistry parameters were small and did not follow a clear trend or pattern suggestive of a serious adverse effect.
that since Finland is situated in the northern hemisphere and Chile in the southern, seasons are opposite, and seasonal However, the changes in the lipid profile and liver function test results should be taken as a signal to pay careful attention variation in the concentrations of testosterone and FSH could influence the results. to the monitoring of these parameters in future studies since similar changes have been associated with androgen MENT has previously been shown to be a potent androgen in animals and to have antigonadotrophic effects (Kumar et al., administration in earlier studies. No reliable conclusions on the safety of MENT can be drawn from these small phase I 1992). In humans, the androgenicity of MENT has been demonstrated by its masculinizing effects in female breast clinical studies.
The Finnish volunteers who participated in the study of six cancer patients (Segaloff et al., 1964; O'Brian 1966) . In these early studies, a pituitary gonadal response to MENT could not MENT injections had significantly lower baseline testosterone concentrations and significantly higher baseline FSH concentrabe shown directly, since methods for the assay of serum gonadotrophin concentrations were unsatisfactory at that time. tions than the Chilean volunteers. It is likely that this is a true difference, since all hormone concentrations were measured Urinary excretion of gonadotrophins was measured and although a tendency toward a decrease in gonadotrophin in the same laboratory, and the control samples did not reveal any significant between-assay variation in testosterone or FSH excretion was observed, these changes were not consistent. Our study is the first to demonstrate that MENT is a potent measurements. A possible cause for this difference is the fact that the Finnish subjects were significantly older than the antigonadotrophic agent in men. In the study of six consecutive i.m. injections a biological response typical of exogenous Chileans (30 Ϯ 2.0 versus 24 Ϯ 0.9 years, P ϭ 0.009).
androgen administration was observed: serum testosterone, LH, FSH and SHBG concentrations decreased significantly during the injection series. Over the dose range studied, there was also a clear dose-response relationship, with the exception of SHBG concentrations. This study supports the idea that small daily doses of MENT could be sufficient for androgen replacement. The suggested route of MENT administration is via subdermal implants (Sundaram et al., 1993) . Future studies with implants will show whether this approach can provide sufficient androgen replacement for a reasonable time.
